2nd Targeted Protein Degredation Europe Summit

Memo

2021 marked a successful year for the protein degradation field with several candidates entering the clinic. As the European centric targeted protein degradation landscape matures and the number of pre-clinical candidates expected to enter clinical development in the next year grows ever more, the 2nd TPD Europe Summit returns, in person, to highlight key challenges and opportunities ahead! Built with biopharma in mind, join us as we take a deep dive into how European leaders of protein degradation are approaching key translational challenges including optimisation of selectivity, bioavailability and PKPD to ensure the safety, efficacy and potency of their clinical pipelines in 2022 and beyond! Be at the heart of the discussion by joining 180+ Senior Scientists, Principal Investigators & Heads of Discovery, Pre-Clinical & Translational Development from Europe and around the globe for two dedicated streams of exciting content over three days to capitalise on this emerging therapeutic class. Take advantage of our group discounts, academic rates and earlybird savings - don't miss out register now for the best rate! Digital Passes Available Tickets https://go.evvnt.com/935273-2?pid=5569,Brochure https://go.evvnt.com/935273-3?pid=5569 Prices:Conference + Focus Day (Drug Developer) GBP 3796.00Conference Only (Drug Developer) GBP 2599.00Conference + Focus Day (Academic & Research Institute) GBP 2996.00Conference Only (Academic & Research Institute) GBP 2099.00Conference + Focus Day (Standard) GBP 4496.00Conference Only (Standard) GBP 2999.00Conference + Focus Day (Drug Developer) - DIGITAL GBP 2596.00Conference Only (Drug Developer) - DIGITAL GBP 1849.00Conference + Focus Day (Academic & Research Institute) - DIGITAL GBP 2096.00Conference Only (Academic & Research Institute) - DIGITAL GBP 1499.00 Speakers: Amine Sadok, Director, Head of Biology Monte Rosa Therapeutics, Benika Pinch, Principal Scientist Novartis Institutes for BioMedical Research, David Wang, VP Business Development Kangpu Biopharmaceuticals, Kevin Moreau, Associate Director PROTAC Safety Science AstraZeneca, Catherine Lindon, Associate Professor University of Cambridge, Department of Pharmacology, Felix Hausch, Professor Technical University Darmstadt, Mikael Altun, Associate Professor Karolinska Institute, Vaishali Dixit, Director, DMPK Kymera Therapeutics, Argyrides Argyrou, Associate Principal Scientist AstraZeneca, Max Cynader, CEO & Co-Founder Primary Peptides, Robin Ketteler, Professor University College London, Sandra Stefanovic-Barrett, Senior Research Associate AstraZeneca, Benedict Cross, CTO PhoreMost, Boxun Lu, Professor Fudan University, Ingo Hartung, Director Merck KGaA, Rob Sellar, CRUK Advanced Clinician Scientist, Honorary Consultant Haematologist UCL Cancer Institute, Jack Jin, COO Primary Peptides, Matthias Brand, VP Biology Proxygen, Michal J. Walczak, CSO Captor Therapeutics, Oskar Hoff, Head of Medicinal Chemistry Celeris Therapeutics, Bernd Boidol, CEO Proxygen, Maria Górna, Principle Investigator, Structural Biology Group University of Warsaw, Matthew Trotter, Vice President, Predictive Sciences Bristol Myers Squibb, Tim Clausen, Senior Scientist Research Institute Of Molecular Pathology, Adam Bond, PhD Student Centre for Targeted Protein Degradation (CeTPD) University of Dundee, Cornelia Wilson, Senior Lecturer and Academic Laboratory Director Canterbury Christ Church University, Manfred Koegl, Director Boehringer Ingelheim, Paola Martinelli, Principal Scientist Boehringer Ingelheim, Agnieszka Konopacka, In Vitro Biologist GlaxoSmithKline, Dennis Gillingham, Associate Professor University of Basel, Ian Churcher, CSO Amphista Therapeutics, Jeffrey Simard, Associate Director, Cell Pharmacology C4 Therapeutics Date and Time: Starts: Tue, Mar 15, 2022 ( 8:30 AM) and Ends: Thu, Mar 17, 2022 ( 5:00 PM) Venue details: Leonardo Royal London Tower Bridge, 45 Prescot Street, Greater London, England, E1 8GP, United Kingdom